市场调查报告书
商品编码
1184285
重组蛋白全球市场规模、份额和行业趋势分析报告:2022-2028 年各产品、最终用户、应用和地区的展望和预测Global Recombinant Proteins Market Size, Share & Industry Trends Analysis Report By Product, By End User, By Application, By Regional Outlook and Forecast, 2022 - 2028 |
在预测期内,重组蛋白的全球市场规模预计将以 10.8% 的复合年增长率增长,到 2028 年将达到 26 亿美元。
该业务的增长预计将受到肉芽肿病、血友病和硬化症等慢性病发病率增加的推动。 此外,重组蛋白产品的改进、对生物製剂和生物仿製药的日益偏好以及其他原因都有助于行业扩张。 COVID-19 的爆发加剧了寻找 SARS-CoV2 病毒治疗和诊断工具的竞赛。
根据 Global Genes 的数据,全球有超过 4 亿人患有罕见遗传病。 这个数字突出了对治疗、改善医疗保健环境和增加公众对健康问题的了解的迫切需要。 药物靶向机制的最新研究和知识对于生产药物至关重要。
队列计划在多个地区创建了生物样本库,使研究人员能够获得高质量的样本,这些样本正在彻底改变治疗工作。 这可能会导致更加强调识别各种疾病的生物标誌物。 例如,2022 年 8 月,FDA 批准 Ayvakit 用于治疗晚期系统性肥大细胞增多症,这是一种罕见的血液疾病。
COVID-19 影响分析
对快速大规模开发 COVID-19 疫苗的需求,加上正在进行的商业製造活动,将对生物製品研究工作产生积极影响,从而推动行业扩大 COVID-19 大流行对蛋白质市场的扩张产生了有利影响。 鑑于 COVID 感染的传播,可以开发结合不同佐剂和抗原亚基的重组蛋白疫苗,这些疫苗对 SARS-CoV-2 感染更有效,并且在中心很容易获得。
市场增长因素
由于慢性病的增加,人们对定製药物的兴趣与日俱增
重组蛋白被认为是为数不多的治疗慢性病的药物之一,随着慢性病的增多,对重组蛋白疗法的需求也越来越大。 据 GLOBOCAN 估计,2020 年墨西哥将出现 195,499 例新癌症病例和 90,222 例癌症相关死亡病例。 一些生物技术,如疫苗、重组蛋白、细胞和基因疗法,对于治疗的个体化至关重要,因此需要纳入个体化医疗的发展。
增加生物製品的研发
由于生物製剂研究和开发的增加,预计重组蛋白市场的需求将会增长。 由于研究週期长和法规滞后,研发行业传统上需要大量资金。 研发支出占全球支出的很大一部分。 各国政府认识到研发是国家发展、国际竞争力和公共利益的重要因素。 因此,研发资金和支出稳步增加。
市场约束
重组蛋白越来越便宜。
重组蛋白是使用实验室培养的细胞製成的,这导致了它们的高成本。 据说占製造成本 80% 的炼油也是一项主要支出。 价格侵蚀被定义为大量玩家进入特定市场,销售没有原创性的相同产品,并以价格合理但没有创意的产品饱和市场。 价格侵蚀是指这些产品在市场上的价格不断下降,从而减缓了市场扩张。
产品展望
按产品划分,它分为生长因子和趋化因子、免疫反应蛋白、结构蛋白、膜蛋白、激□蛋白、调节蛋白、重组代谢□、粘附分子和受体以及其他重组蛋白。 到 2021 年,免疫反应蛋白预计将占销售额的很大一部分。 细胞因子是体内一组重要的蛋白质。 这些小蛋白质充当免疫系统的信使。 它充当免疫系统的通信网络,并作为对威胁的反应而产生。 免疫系统细胞有时通过彼此直接接触相互作用,但更常见的是通过分泌细胞因子,它们可以作用于附近或远处的细胞。
应用展望
按应用分为药物发现和市场开发、生物製药生产、生物技术研究、学术研究、诊断和其他应用。 生物技术研究将在 2021 年占据很大的收入份额。 重组蛋白有助于阐明生物的基本原理。 这些分子可用于定位和查明由特定基因编码的蛋白质,以及其他基因在细胞信号传导、代谢、生长、复製、死亡和翻译中的作用。了解更多关于它们如何参与以下过程的信息、转录和蛋白质修饰。
最终用户视角
基于最终用户,重组蛋白市场细分为製药和生物製药行业、生物技术行业、学术研究机构、合同研究机构和其他最终用户。 合同研究实验室预计将在 2021 年占市场收入的很大一部分。 研发行业对学术机构和公司之间的伙伴关係和合作的投资有所增加。 例如,辉瑞的治疗创新中心 (CTI) 充当医疗保健系统利益相关者之间互动的论坛。
区域展望
按地区划分,重组蛋白市场分为北美、欧洲、亚太地区和 LAMEA。 2021年重组蛋白的主要区域市场是北美。 慢性病和遗传病的高患病率;研发资金;由于製药业的大量存在以及分析仪器在药物发现和研发中的应用,北美似乎在全球市场中占有很大份额。
The Global Recombinant Proteins Market size is expected to reach $2.6 billion by 2028, rising at a market growth of 10.8% CAGR during the forecast period.
Recombinant proteins have a huge future in the study and development of cancer therapies. Examples of recombinant proteins used in cancer therapy research include growth factors, immunological checkpoints, and cell damage & oxidative stress proteins (preclinical stage). The utilization of recombinant proteins including immunological checkpoint, antibodies, and growth factors, for targeted purposes has risen as a result of a greater knowledge of neoplastic signalling cascades and the proteins involved in them.
Researchers utilise these proteins frequently to study how cancer signalling pathways and functions. Research uses recombinant immune checkpoints that directly target programmed death-1 (PD-1) and programmed death ligand-1 and 2 (PD-L1), including PD-1/PD-L1 Inhibitor 1 and PD-1/PD-L1 Inhibitor 2. Aside from that, proteins like CD40 Ligand/TRAP, CD226, and Human CellExp CTLA4/CD152 are often employed in studies on cancer therapy.
Growth in the business is predicted to be fueled by the increased incidence of chronic disorders such granulomatous disease, haemophilia, and sclerosis. Additionally, improved recombinant protein products, the growing preference for biologics and biosimilars, and other reasons all contribute to the industry's expansion. The race to discover cures and diagnostic tools for the SARS-CoV2 virus was fuelled by the COVID-19 epidemic.
With over 400 million people worldwide suffer from uncommon genetic illnesses, according to Global Genes. This figure demonstrates the urgent need for therapies, an improvement in healthcare environments, and increased public knowledge of health issues. A critical instrument for the creation of medicines is the requirement for cutting-edge research and knowledge of drug targeting mechanisms.
Cohort programmes have helped several regions create biobanks that give researchers access to high-quality samples that will revolutionise treatment efforts. This may lead to a greater emphasis on the identification of biomarkers for various illnesses. As an illustration, the FDA approved Ayvakit in August 2022 to address advanced systemic mastocytosis, a rare blood disorder.
COVID-19 Impact Analysis
The requirement for the COVID-19 vaccine to be developed quickly and on a large scale, as well as its ongoing commercial manufacturing activities, had a favourable effect on the development of biologics-based research initiatives and ultimately helped the industry's expansion. The COVID-19 pandemic had a favourable effect on the expansion of the proteins market. Recombinant protein vaccines may be developed with a combination of subunits of different adjuvants and antigens that will be more effective against SARS-CoV-2 infections and be readily available in the centre, it was suggested in light of the growth in COVID infection.
Market Growth Factors
Growing Emphasis On Customised Medicine Due To An Increase In The Prevalence Of Chronic Diseases
Recombinant proteins are one of the few recognised treatments for such conditions, and as chronic illnesses are on the rise, there is a significant demand for recombinant protein therapies. According to GLOBOCAN, there were estimated 195,499 new cancer cases and 90,222 cancer-related deaths in Mexico in 2020. Several biotechnologies, including vaccines, recombinant proteins, and cell and gene therapies, must be incorporated into the development of personalised medicine since they are essential to the personalization of care.
Increasing Biologics Research And Development
The market for recombinant proteins is anticipated to expand in demand due to the increased research and development on biologics. The R&D industry has traditionally required a lot of capital because of lengthy study periods and regulatory delays. Consumption on R&D accounts for a considerable share of global spending. Governments acknowledge R&D as a crucial factor in a nation's development, global competitiveness, and public good. R&D funding and spending have risen steadily as a result.
Market Restraining Factors
Recombinant proteins are getting cheaper.
Recombinant Proteins are made in labs using cells that have been grown, which contributes to their expensive price. Purification of these medications, which can make up as much as 80% of the manufacturing costs, is one of the major expenses. Price erosion is defined as when many players enter a particular market and sell identical products without any uniqueness, saturating the market with less creative and reasonably priced goods. Price erosion is the constant drop in the price of these products in a given market, which slows down market expansion.
Product Outlook
Based on Product, the market for recombinant proteins is classified into growth factors and chemokines, immune response proteins, structural proteins, membrane proteins, kinase proteins, regulatory proteins, recombinant metabolic enzymes, adhesion molecules and receptors, and other recombinant proteins. Immune response proteins are expected to command a sizable sales share in 2021. A crucial group of proteins in the body are cytokines. These little proteins act as immune system messengers. They serve as the immune system's network of communication and are created in reaction to a threat. Immune system cells can sometimes interact by touching one another directly, but more frequently, they do so via secreting cytokines, which can operate on other cells nearby or far away.
Application Outlook
Based on application, the market Drug Discovery & Development, Biopharmaceutical Production, Biotechnology Research, Academic Research Studies, Diagnostics, and Other Applications. The biotechnology research command a significant revenue share in 2021. Recombinant proteins aid in illuminating an organism's basic and underlying principles. These molecules can be used to identify and pinpoint the location of the protein that a particular gene encodes, as well as to learn more about how other genes are involved in processes such as cell signalling, metabolism, growth, replication, and death, as well as translation, transcription, and protein modification.
End User Outlook
Based on End User, the Recombinant Proteins Market is divided in pharmaceutical and biopharmaceutical industry, biotechnology industry, academic research institutes, contract research organisations, and other end users. Contract Research Organizations are expected to account for a sizable portion of market revenue in 2021. The R&D industry saw increased investments in regards to partnerships and collaborations between academic institutions and businesses. For instance, the Center for Therapeutic Innovation (CTI) at Pfizer serves as a forum for interaction among stakeholders in the healthcare system.
Regional Outlook
Based on geography, the Recombinant Proteins Market is classified into North America, Europe, Asia Pacific, and LAMEA. The leading regional market for recombinant proteins in 2021 was North America. The high prevalence of chronic and genetic diseases, the availability of funding for R&D, government initiatives for R&D in the pharmaceutical industry, the growing use of life science techniques in research and academia, the significant presence of major pharmaceutical and biotechnology organizations, and the application of analytical instruments in drug discovery and development are all factors that contribute to North America holding a significant share of the global market.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
Strategies Deployed in Recombinant Proteins Market
Nov-2022: Abcam comes into agreement with NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research. Through this agreement, Abcam RabMAb™ recombinant antibodies would be produced as part of the first 64-plex protein panel for NanoString's CosMx™ Spatial Molecular Imager (SMI). Additionally, this agreement would open the full capability of spatial biology and help enhance care for people with cancer.
2022-Jul: Bio-Rad Laboratories launched EconoFit Columns, a low-pressure prepacked chromatography column pack. The EconoFit columns are created for resin screening, enabling customers that are designing protein purification workflows to choose the optimal chemistry for various targets. The products offer run-to-run uniformity to support preparative scale purifications and method advancement for the latest target proteins, as well as to improve existing workflows.
Feb-2022: Abcam came into agreement with Twist Bioscience Corporation, a synthetic biology company. Under this agreement, Abcam would use a proprietary Twist VHH phage library for antibody development, discovery, and commercialization for research and diagnostic application. Moreover, Twist Bioscience grants Abcam the right to perform research and development activities utilizing Twist single domain (VHH) synthetic antibody library.
Jan-2022: Thermo Fisher Scientific Inc. completed the acquisition PeproTech, Inc., a leading developer, and manufacturer of recombinant proteins. Through this acquisition, PeproTech's recombinant proteins suite aligns with Thermo Fisher's cell culture media products and would allow Thermo Fisher to offer customers significant advantages through an integrated offering.
2021-Nov: Abcam partnered with Nautilus Biotechnology, Inc., a development-stage life sciences company. Under this partnership, Both companies would focus on the combined advancement of affinity binding reagents used on the Nautilus proteomic analysis system and would broaden in the upcoming time to the large-scale manufacturing and supply of reagents for production.
Mar-2021: Bio-Techne Corporation released Cultrex™ UltiMatrix, a hydrogel extracellular matrix that is beneficial for cultivating pluripotent stem cells and organoids in terms of performance and consistency. The product develops Matriz hydrogels that support the growth use of pluripotent stem and organoid cells for drug research, commercialize medicine, and regenerative medicine.
Nov-2020: Merck signed an agreement with Donghao Lansheng (Group) Co., Ltd., a large modern service industry. This agreement would drive a new process that helps the custom clearing of research material for analytical use and biomedical innovation, through this Merck would be able to process shipments with the technical dossier and fewer application needs.
Nov-2019: Abcam plc announced a partnership with BrickBio, a Tiger Gene suite company and have specialization in site-specific protein modification. Through this partnership, Abcam would have full rights to the platform for the formation of novel conjugation-ready recombinant products for the research equipment market and to produce the platform over its recombinant antibody and protein offering for diagnostic use.
Apr-2019: Bio-Techne Corporation Collaborated with Elpiscience BioPharma, a clinical-stage biopharmaceutical company. Through this collaboration, both companies aimed to advance anti-cancer therapeutics and boost the development of the latest biologics to meet the medical requirements in Oncology.
Apr-2018: Proteintech Group acquired HumanZyme, a manufacturer of recombinant human proteins. Through this acquisition, the company would strengthen its place as a manufacturer of antibodies, ELISA kits, and proteins.
Market Segments covered in the Report:
By Product
By End User
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures